We evaluated the association between baseline uric acid and the primary composite outcome of doubling of interstitium or ESRD from interstitial fibrosis and tubular atrophy ( IF/TA ) in the Angiotensin II Blockade for Chronic Allograft Nephropathy ( ABCAN ) Trial participants .